analytics_image
Viral Vector and Plasmid DNA Manufacturing Market Size, Share & Growth Forecast by 2035\
Vantage Market Research
Vantage Market Research

Reports - Viral Vector and Plasmid DNA Manufacturing Market

iconBiotechnology and Life Sciences

Viral Vector and Plasmid DNA Manufacturing Market

Viral Vector and Plasmid DNA Manufacturing Market by Product Type (Plasmid DNA, Viral Vector, Non-viral Vector), by Application (Cancer, Genetic Disorder, Infectious Disease, Other Applications), by Region (North America, Europe, Asia Pacific, Latin America) - Historic Data (2021 - 2023) & Forecast Period (2025 - 2035)

ppt icon
pdf icon
xlsx icon
power bi icon
immediate delivery icon

Industry Leaders Trust Us For Actionable Intelligence

Revenue Insights

Market Size in 2024

USD 6.4 Billion

Market Size By 2035

USD 30.91 Billion

CAGR (2025 - 2035)

15.40%

Largest Region

North America

Fastest Region

Asia Pacific

Base Year

2024

Historic Data

2021 - 2023

Forecast Period

2025 - 2035

Segments Covered

By Product Type, By Application, By Region

Report Coverage

The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.

Overview

Market Synopsis:

The global Viral Vector and Plasmid DNA Manufacturing Market is valued at USD 6.4 Billion in 2024 and is projected to reach a value of USD 30.91 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 15.40% between 2025 and 2035. The need for viral vector-based vaccinations for infectious illnesses is growing in tandem with the current shift in the treatment paradigm of various life-threatening diseases through sophisticated therapeutics. As a result, more Viral Vector and Plasmid DNA Manufacturing are being used in the R&D of new medicines, pushing the market for Viral Vector and Plasmid DNA Manufacturing manufacturing.

Viral Vector and Plasmid DNA Manufacturing Market Size, 2024 To 2035 (USD Billion)

In addition, the COVID-19 epidemic has offered profitable prospects for market participants. For example, in December 2020 and February 2021, multinational pharmaceutical companies such as AstraZeneca and Janssen Pharmaceuticals developed COVID-19 viral vector-based vaccines, respectively. Aside from these firms, a number of viral vector-based vaccines are now in development. As a result, demand for viral vectors has increased, resulting in increased revenue for viral vector manufacturers.


Rising R&D Funding and Growing Initiatives

The availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research on viral vector gene therapies, and the recent approval of many viral vector gene treatments are propelling this industry forward. As a result of the growing need for advanced clinical therapies and the growing importance of an expanding discipline in medical science, the Viral Vector and Plasmid DNA Manufacturing market has developed dramatically. Adenoviruses, baculoviruses, herpes simplex viruses, and other viral vectors are increasingly being used in the development of new drugs and vaccines.


Manufacturing Challenges

Manufacturing challenges associated with large-scale vector production may limit the markets growth. Because of increased investments by healthcare stakeholders in delivering innovative care delivery models, sophisticated digital technology, and many other things, the global healthcare industry has seen an increase in the availability of technologically advanced healthcare equipment. This has aided in the development of a sophisticated health ecosystem around the world. The growing healthcare infrastructure will open up new prospects in the industry, increasing demand for Viral Vector and Plasmid DNA Manufacturing around the world. However, legal, technical, and ethical problems involved with gene therapy, as well as production capacity restrictions and manufacturing challenges associated with large-scale vector production, are important factors limiting market expansion.


Market Segmentation:

The Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented by Product Type (Plasmid DNA, Viral Vector, And Non-Viral Vector), By Application (Cancer, Genetic Disorder, Infectious Disease, And Other Applications). By Region, North America, Europe, Asia Pacific, Latin America, Middle East & Africa


North America to Continue Dominating the Viral Vector and Plasmid DNA Manufacturing Market

North America, Europe, and Asia Pacific accounted for the greatest proportion of the Viral Vector and Plasmid DNA Manufacturing market in 2024. Factors such as the increase in the number of well-established Viral Vector and Plasmid DNA Manufacturing companies and research institutes in the United States and Canada, a large number of ongoing research studies, and the overall growth of the healthcare sector on a global scale are among the few factors expected to contribute to the markets growth. One of the primary causes leading to the growing demand for Viral Vector and Plasmid DNA Manufacturing techniques and technologies among academic and research organisations, as well as healthcare firms in North America, is increased R&D spending.




Key Players:

Fujifilm Diosynth Biotechnologies, Fujifilm Diosynth Biotechnologies (US), SIRION Biotech (Germany), Thermo Fisher Scientific (US), Merck KGaA Inc. (US), Cognate BioServices Inc. (Cobra Biologics) (US)​​ are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market.


Viral Vector and Plasmid DNA Manufacturing market is segmented as follows:

Market Segmentation

ParameterDetails
Segment Covered

By Product Type

  • Plasmid DNA (16.7%)
  • Viral Vector
  • Non-viral Vector

By Application

  • Cancer (28.9%)
  • Genetic Disorder
  • Infectious Disease
  • Other Applications

By Region

  • North America (U.S., Canada, Mexico) (48.9%)
  • Europe (Germany, France, U.K., Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, South-East Asia, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa
Companies Covered
  • Fujifilm Diosynth Biotechnologies (US)
  • SIRION Biotech (Germany)
  • Thermo Fisher Scientific (US)
  • Merck KGaA Inc. (US)
  • Cognate BioServices Inc. (Cobra Biologics) (US)​ are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market.
Customization ScopeEnjoy complimentary report customization—equivalent to up to 8 analyst working days—with your purchase. Customizations may include additions or modifications to country, regional, or segment-level data.
Pricing and purchase optionsAccess flexible purchase options tailored to your specific research requirements. Explore purchase options

Viral Vector and Plasmid DNA Manufacturing market is tabulated as follows:



Report coverage & Deliverables

Our PDF Reports And Online Dashboard Will Help You Stay Ahead In The Market.

    Key features include:

  • Check
    Competitive benchmarking
  • Check
    Historical data and future forecasts
  • Check
    Company-wise revenue breakdown
  • Check
    Regional growth opportunities
  • Check
    Latest market trends and dynamics
  • Check
    Impact of emerging technologies like AI and automation
  • Check
    Key regulatory updates and ESG considerations

FAQ‘s

Related Reports

vantage logo

Vantage Market Research & Consultancy Services is all about providing accurate and reliable market intelligence to its clients for the seamless execution of their business growth strategies.

© 2025 Vantage Market Research. All right reserved
Secured Bysecured by